Pila Pharma Q3 2022: Funding In Focus
Research Note
2022-10-26
12:13
Redeye leaves its view on Pila Pharma following its report for the third quarter of 2022. We comment on yesterday's rights issue, the content in the report, and lower our Base case.
FE
Filip Einarsson
Disclosures and disclaimers